TB/Non-TB Mycobacterial Infections
M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.
15 Jun, 2022 | 10:47h | UTC
Commentary on Twitter
This meta-analysis of pregnant patients treated for multi-drug-resistant tuberculosis (MDR-TB) found 73% treatment success and 73% favorable pregnancy outcomes, with adverse events (incl liver/kidney impairment, hearing loss) in more than half of patients. https://t.co/Mx5RLiwhU9
— JAMA Network Open (@JAMANetworkOpen) June 10, 2022
Systematic Review: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
25 May, 2022 | 10:46h | UTCSummary: Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs – Cochrane Library
Modeling Study: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment.
25 May, 2022 | 10:44h | UTCInvited Commentary: Investing in drug-resistant tuberculosis household contact management and preventive treatment – The Lancet Global Health
WHO calls for shorter drug course for resistant TB.
4 May, 2022 | 11:08h | UTCWHO calls for shorter drug course for resistant TB – CIDRAP
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization
Review: Anti-tuberculosis treatment strategies and drug development: challenges and priorities.
1 May, 2022 | 23:23h | UTCAnti-tuberculosis treatment strategies and drug development: challenges and priorities – Nature Reviews Microbiology (if the link is paywalled, try this one)
News Release: A major update on global tuberculosis fight – Hackensack Meridian Health
Commentary on Twitter
Anti-tuberculosis treatment strategies and drug development: challenges and prioritieshttps://t.co/nZlcEwTDLP
In this Review, Dartois and Rubin explore challenges and priorities for anti-tuberculosis treatment strategies and drug development.@vdartois1 pic.twitter.com/t6RQoaFb8C
— Nature Reviews Microbiology (@NatureRevMicro) April 27, 2022
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.
27 Apr, 2022 | 07:52h | UTC
Drug resistant TB – latest developments in epidemiology, diagnostics and management.
13 Apr, 2022 | 10:09h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment
Canadian Tuberculosis Standards – 8th Edition.
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Canadian Tuberculosis Standards – 8th Edition.
28 Mar, 2022 | 09:46h | UTCChapter 1: Epidemiology of tuberculosis in Canada
Chapter 2: Transmission and pathogenesis of tuberculosis
Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis
Chapter 4: Diagnosis of tuberculosis infection
Chapter 5: Treatment of tuberculosis disease
Chapter 6: Tuberculosis preventive treatment in adults
Chapter 7: Extra-pulmonary tuberculosis
Chapter 8: Drug-resistant tuberculosis
Chapter 9: Pediatric tuberculosis
Chapter 10: Treatment of active tuberculosis in special populations
Chapter 11: Tuberculosis contact investigation and outbreak management
Chapter 13: Tuberculosis surveillance and tuberculosis infection testing and treatment in migrants
Chapter 14: Prevention and control of tuberculosis transmission in healthcare settings
Chapter 15: Monitoring tuberculosis program performance
Systematic Review: Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status.
28 Mar, 2022 | 08:54h | UTC
Cochrane Special Collection: Diagnosing tuberculosis.
25 Mar, 2022 | 09:57h | UTCDiagnosing tuberculosis – Cochrane Library
M-A: Tuberculosis screening among HIV-positive inpatients.
25 Mar, 2022 | 08:35h | UTC
Commentary on Twitter
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis https://t.co/DqTUr2JxHy In setting where TB prevalence is > 10%, WHO now strongly recommends molecular rapid diagnostic testing in all medical inpatient PWH.
— Carlos del Rio (@CarlosdelRio7) March 24, 2022
RCT: High dose Rifampicin with or without Levofloxacin vs. standard of care for pediatric tuberculous meningitis.
24 Mar, 2022 | 08:12h | UTC
New WHO guidelines on the management of tuberculosis in children and adolescents.
22 Mar, 2022 | 09:52h | UTC
A validated score for evaluating spinal instability to assess surgical candidacy in active spinal tuberculosis—an evidence based approach and multinational expert consensus study.
21 Mar, 2022 | 08:21h | UTC
Cohort Study: TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.
16 Mar, 2022 | 08:44h | UTC
Review: Mycobacterial skin infection.
14 Mar, 2022 | 00:59h | UTCMycobacterial skin infection – Current Opinion in Infectious Diseases
RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.
10 Mar, 2022 | 11:03h | UTCNews Release: Treatment length reduced for children with tuberculosis – University College London
Commentary on Twitter
Completing 6 months of treatment for tuberculosis in children is a challenge. In this open-label trial involving 1204 children in sub-Saharan Africa and India, 4 months of antituberculosis therapy was noninferior to 6 months of therapy. https://t.co/zkD4URWMru pic.twitter.com/LFR6ZzTKgs
— NEJM (@NEJM) March 9, 2022
Pictorial Review | Extrapulmonary tuberculosıs: an old but resurgent problem.
9 Mar, 2022 | 08:33h | UTCExtrapulmonary tuberculosıs: an old but resurgent problem – Insights into Imaging
New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis.
27 Feb, 2022 | 22:49h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Guideline: Screening for Tuberculosis Disease
New WHO Recommendations to Prevent Tuberculosis
CDC Guidelines for the Treatment of Latent Tuberculosis Infection
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Guidelines for the Management of TB in Adults Living with HIV
Commentary on Twitter
Clinicians: @CDC_TB released interim guidance on a new regimen to treat #TB disease. Learn more about the 4-month regimen containing rifapentine, moxifloxacin, isoniazid, and pyrazinamide for people with drug-susceptible pulmonary TB disease in the U.S.: https://t.co/eOcR34tYJu pic.twitter.com/EFGMwAwN7c
— MMWR (@CDCMMWR) February 25, 2022
Essay: Tuberculosis in times of COVID-19.
15 Feb, 2022 | 10:16h | UTCTuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health
Related:
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
Global tuberculosis progress reversed by COVID-19 pandemic.
How COVID is derailing the fight against HIV, TB and malaria.
How COVID hurt the fight against other dangerous diseases
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
Tuberculosis and Covid-19: Fighting a deadly syndemic
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments.
11 Feb, 2022 | 08:29h | UTC
Systematic Review: Video-observed therapy vs. directly observed therapy in patients with tuberculosis.
9 Feb, 2022 | 08:35h | UTCVideo-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis – American Journal of Preventive Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Our latest publication on @AmJPrevMed : Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. Implementation of VOT improved medication adherence and bacteriological resolution compared with that of DOT in TB patients.https://t.co/xcWzrxLbHB? pic.twitter.com/4ldYJ2umd7
— Bang Truong (@bangphd_epi) December 13, 2021
Cluster-Randomized Trial: A multicomponent diagnostic strategy (on-site molecular testing for tuberculosis, guided restructuring of clinic workflows, and monthly feedback of quality metrics) significantly improved the rates of a confirmed diagnosis of tuberculosis within 14 days after presentation.
8 Feb, 2022 | 08:43h | UTCMulticomponent Strategy with Decentralized Molecular Testing for Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A cluster-randomized trial in 20 Ugandan health centers compared a multicomponent TB strategy with routine care. The intervention led to greater numbers of patients being tested for, receiving a diagnosis of, and being treated for confirmed TB. https://t.co/PcJDC1I0CY pic.twitter.com/AT99QVOn2S
— NEJM (@NEJM) December 28, 2021
RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
26 Jan, 2022 | 01:58h | UTC
Commentary on Twitter
In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266
— JAMA Network Open (@JAMANetworkOpen) January 20, 2022
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
11 Jan, 2022 | 01:33h | UTC
Commentary on Twitter
In @NEJM today, @TerezaKasaeva @doctorsoumya and I write about
Covid-19’s devastating impact on tuberculosis care & offer suggestions for recoveryhttps://t.co/buOEOPVWwM pic.twitter.com/BfOK3X3MuU
— Madhu Pai, MD, PhD (@paimadhu) January 5, 2022